RMTI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
RMTI is not a good buy right now for an impatient trader. There is no Intellectia buy signal, the latest quarter (2025/Q3) showed sharp YoY deterioration in revenue/margins, and near-term pattern odds lean slightly negative. The best setup would require either a clean reclaim of the 1.12 pivot with follow-through toward 1.25+, or a controlled bounce off ~0.99 support with stronger momentum—neither is present now.
Price/levels: RMTI at ~$1.05 is below the pivot (1.122) and sitting between S1 (0.992) and R1 (1.252). This positioning suggests the stock is still in a fragile zone where a quick dip to test ~0.99 is plausible. Momentum: MACD histogram is slightly positive (0.00423) but positively contracting, implying upside momentum is weakening rather than accelerating. RSI(6) ~49.96 is neutral, confirming no strong trend. Trend/odds: Similar-pattern stats show a 60% chance of -0.81% next day and -0.95% next week (only +0.35% next month), which does not favor an immediate entry.
Intellectia Proprietary Trading Signals
No recent news in the past week (no fresh negative catalyst).
Call-skewed options open interest suggests some market participants are positioned for upside.
Analyst H.C. Wainwright still maintains a Buy rating (despite lowering the target).
Fundamentals weakened materially in the latest reported quarter (2025/Q3), pressuring confidence in near-term upside.
No Intellectia (AI Stock Picker/SwingMax) buy signal to justify an impatient entry.
Near-term pattern odds tilt slightly negative (next day/week).
Extremely high implied volatility suggests heightened uncertainty and choppy trading conditions.
No recent news catalyst to re-rate the stock upward immediately.
Latest quarter: 2025/Q3. Revenue: $15.93M, down -43.75% YoY (significant contraction). Net income: -$1.753M, down -222.50% YoY (loss widened). EPS: -$0.05, down -225.00% YoY. Gross margin: 17.4%, down -21.02% YoY (profitability pressure). Overall: The quarter shows clear negative growth and margin trends, which typically caps near-term rallies unless a strong catalyst appears.
Latest update (2025-11-13): H.C. Wainwright reiterated Buy but cut the price target to $2.50 from $3 after a slight Q3 top-line miss and reduced longer-term forecasts. Wall Street pro view (based on this coverage): Pros: Still sees upside versus ~$1.05 and acknowledges a more diversified revenue base. Cons: Lowered forecasts and noted the company may not benefit from large contracts as much as in the past—suggesting a more muted growth runway and less dependable big-step revenue catalysts.
